Forget Arena Vs. Vivus - Zafgen May Be The Ultimate Winner
by Stephen Simpson
As an investor and writer with no financial stake in any of the companies involved, watching the message board battles between Arena (ARNA) and Vivus (VVUS) shareholders is good theater. Both companies have FDA-approved drugs on the market that are effective in helping obese people lose weight, but neither Arena's Belviq nor Vivus's Qsymia look like "the one obesity drug to rule them all". Belviq is hampered by modest efficacy, while Qsymia can produce scary side effects and has a more limited marketing effort behind it. read more »
Get Seeking Alpha notifications with our iPhone App | Android App | iPad App
More on ARNA
Arena's Belviq - The Path To $150 Million In Sales by Spencer Osborne
Arena's Belviq: Finding The Target Patients by Spencer Osborne
New Analysis Of Arena's Belviq Is Good News For Responders And Shareholders by Reasonable Risk
Other articles that mention ARNA
2 Plays For The Speculative Investor by Michael J. Ray
Vivus Script Numbers Showing Traction by Spencer Osborne
Is The Anti-Obesity Space Going To Get Crowded? by Spencer Osborne
Why are you receiving this? You subscribed to real-time article alerts at Seeking Alpha.
If this email was forwarded to you and you wish to subscribe to this email, click here.
Manage your emails:
Get alerts on additional tickers and manage all your email alert choices here
I’m getting too many emails: manage your email alert choices
I’m no longer following ARNA: unsubscribe from all ARNA email alerts
This type of alert isn't helpful to me: unsubscribe from article alerts on ARNA
To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders.
Sent by Seeking Alpha, 345 7th Ave. Suite 1400 New York, NY 10001
